MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the following upcoming investor conferences:
The Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square in New York, NY from September 11th-13th.
The Sidoti Small-Cap Conference, which is being held virtually from September 20th-21st.
A live audio webcast of the presentation will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com. An archive of the webcast will be available for replay following the conference.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Last Trade: | US$13.66 |
Daily Change: | 0.13 0.96 |
Daily Volume: | 198,343 |
Market Cap: | US$327.840M |
March 05, 2025 February 18, 2025 February 04, 2025 January 13, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load